Showing 1 - 5 results of 5 for search 'Johannes C. Melms', query time: 0.04s Refine Results
  1. 1
    Alpha-fetoprotein (AFP) as tumor marker in a patient with urothelial cancer with exceptional response to anti-PD-1 therapy and an escape lesion mimic

    Alpha-fetoprotein (AFP) as tumor marker in a patient with urothelial cancer with exceptional response to anti-PD-1 therapy and an escape lesion mimic by Johannes C. Melms, Rohit Thummalapalli, Kristin Shaw, Huihui Ye, Leo Tsai, Rupal S. Bhatt, Benjamin Izar

    Published 2018-09-01
    Get full text
    Article
  2. 2
    KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response

    KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response by Charles G Drake, Benjamin Izar, Casey R Ager, Aleksandar Obradovic, Matthew Chaimowitz, Catherine Spina, Mingxuan Zhang, Shruti Bansal, Somnath Tagore, Collin Jugler, Meri Rogava, Johannes C Melms, Patrick McCann, Matthew C Dallos

    Published 2023-09-01
    Get full text
    Article
  3. 3
    Contribution of Trp63CreERT2-labeled cells to alveolar regeneration is independent of tuft cells

    Contribution of Trp63CreERT2-labeled cells to alveolar regeneration is independent of tuft cells by Huachao Huang, Yinshan Fang, Ming Jiang, Yihan Zhang, Jana Biermann, Johannes C Melms, Jennifer A Danielsson, Ying Yang, Li Qiang, Jia Liu, Yiwu Zhou, Manli Wang, Zhihong Hu, Timothy C Wang, Anjali Saqi, Jie Sun, Ichiro Matsumoto, Wellington V Cardoso, Charles W Emala, Jian Zhu, Benjamin Izar, Hongmei Mou, Jianwen Que

    Published 2022-09-01
    Get full text
    Article
  4. 4
    Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial

    Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomi... by Nasser K. Altorki, Zachary H. Walsh, Johannes C. Melms, Jeffery L. Port, Benjamin E. Lee, Abu Nasar, Cathy Spinelli, Lindsay Caprio, Meri Rogava, Patricia Ho, Paul J. Christos, Ashish Saxena, Olivier Elemento, Bhavneet Bhinder, Casey Ager, Amit Dipak Amin, Nicholas J. Sanfilippo, Vivek Mittal, Alain C. Borczuk, Silvia C. Formenti, Benjamin Izar, Timothy E. McGraw

    Published 2024-01-01
    Get full text
    Article
  5. 5
    Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial

    Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial... by Nasser K. Altorki, Zachary H. Walsh, Johannes C. Melms, Jeffery L. Port, Benjamin E. Lee, Abu Nasar, Cathy Spinelli, Lindsay Caprio, Meri Rogava, Patricia Ho, Paul J. Christos, Ashish Saxena, Olivier Elemento, Bhavneet Bhinder, Casey Ager, Amit Dipak Amin, Nicholas J. Sanfilippo, Vivek Mittal, Alain C. Borczuk, Silvia C. Formenti, Benjamin Izar, Timothy E. McGraw

    Published 2023-12-01
    Get full text
    Article

Search Tools: